CFB
CSTL icon

Cullen/Frost Bankers’s Castle Biosciences CSTL Stock Holding History

Cullen/Frost Bankers’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-2,685
Closed -$61K – 1155
2023
Q1 		$61K Hold
2,685
– – ﹤0.01% 688
2022
Q4 		$63.2K Sell
2,685
-70
-3% -$1.62K ﹤0.01% 664
2022
Q3 		$72K Hold
2,755
– – ﹤0.01% 649
2022
Q2 		$60K Sell
2,755
-2,465
-47% -$57.3K ﹤0.01% 674
2022
Q1 		$234K Sell
5,220
-210
-4% -$8.68K ﹤0.01% 497
2021
Q4 		$233K Buy
5,430
+1,605
+42% +$83.9K ﹤0.01% 511
2021
Q3 		$254K Buy
3,825
+20
+0.5% +$1.41K 0.01% 486
2021
Q2 		$279K Hold
3,805
– – 0.01% 487
2021
Q1 		$260K Buy
+3,805
New +$286K 0.01% 481

Other funds holding CSTL

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
KCM
Kornitzer Capital Management Shawnee Mission, Kansas $4.65B AUM 23.83% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Cullen/Frost Bankers's CSTL Position: Q2 2023 in Review

Cullen/Frost Bankers sold out of Castle Biosciences (CSTL) in Q2 2023, closing a stake of 2,685 shares — an estimated $61K sold.

Cullen/Frost Bankers first reported a position in CSTL in Q1 2021 and held it in 9 quarters. The position peaked at $279K in Q2 2021. 130 funds tracked by Wall St. Rank hold CSTL as of Q2 2023.

  • Cullen/Frost Bankers reported no remaining Castle Biosciences position as of Q2 2023 after selling out during the quarter.
  • Cullen/Frost Bankers sold 2,685 Castle Biosciences shares in Q2 2023, an estimated $61K.
  • Cullen/Frost Bankers first reported a position in Castle Biosciences in Q1 2021 and held it in 9 quarters.
  • Cullen/Frost Bankers's Castle Biosciences position peaked at $279K in Q2 2021.
  • 130 funds tracked by Wall St. Rank held Castle Biosciences as of Q2 2023.

Based on Cullen/Frost Bankers's 13F filing for Q2 2023, filed 4 Aug 2023.